Dr. Viviano is the Chief Medical Officer in the Office of Clinical Evidence and Analysis (OCEA) in the Center for Devices and Radiological Health at FDA. In OCEA, he is primarily involved in clinical study initiatives, including utilization of real world data across the total product lifecycle. He was on the NESTcc Data Quality subcommittee.
He previously served as the Clinical Deputy Office Director in the Office of GastroRenal, ObGyn, General Hospital, and Urology Devices (OHT3). Upon joining the FDA in 2015, he was the sole Urology medical officer in CDRH, responsible for the clinical review of all urologic devices, including the first submissions for high intensity focused ultrasound devices for prostate ablation. He was also the principal investigator for an FDA-led project identifying patient preferences in prostate cancer treatment.
Prior to joining the FDA, he was an Assistant Professor in the Division of Urology at Duke University where his practice focused on General Urology and Men’s Health. Prior to Duke, he was in private practice in Connecticut. He received his medical education at the University of Connecticut and his PhD in Toxicology from the University of North Carolina at Chapel Hill.
Conflict of Interest Disclosures: No Conflicts